Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge About Psychosocial Interventions Among Individuals With Severe Mental Illness: Results of a Cross-Sectional Study.

Community mental health journal·2026
Same author

Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D : Case reports.

Wiener klinische Wochenschrift·2026
Same author

Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients.

Journal of neurology·2026
Same author

Corrigendum to "Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades." Gastrointest Endosc 2025;102:733-7.

Gastrointestinal endoscopy·2026
Same author

Sorghum Starch and Protein Digestibility: Mechanisms, Modifications, and Health Implications.

Foods (Basel, Switzerland)·2026
Same author

[Between Closeness and Distance: A New Instrument Proves Its Value in Forensic Psychiatry Practice].

Fortschritte der Neurologie-Psychiatrie·2026

Related Experiment Video

Updated: Jul 1, 2026

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
06:25

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

Initial experience with ropinirole PR (prolonged release).

Wolfgang H Jost1, Carsten Buhmann, Gerd Fuchs

  • 1Dept. Neurology, Deutsche Klinik für Diagnostik, Germany. jost.neuro@dkd-wiesbaden.de

Journal of Neurology
|September 20, 2008
PubMed
Summary
This summary is machine-generated.

The new ropinirole prolonged release (PR) formulation offers effective Parkinson's disease treatment with once-daily dosing. Switching from immediate release (IR) to PR ropinirole is well-tolerated and improves patient convenience.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

Related Experiment Videos

Last Updated: Jul 1, 2026

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
06:25

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Ropinirole, a dopamine agonist, has a decade-long history in Parkinson's disease (PD) management.
  • Current immediate-release (IR) formulations require multiple daily doses.
  • A novel prolonged-release (PR) formulation has been developed for ropinirole.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of switching PD patients from ropinirole IR to ropinirole PR.
  • To assess the benefits of a once-daily dosing regimen for ropinirole therapy.

Main Methods:

  • Patients with Parkinson's disease were switched from ropinirole IR to ropinirole PR.
  • The switch was performed overnight at the nearest equivalent total daily dose.
  • Patient acceptance, tolerability, and clinical outcomes were monitored.

Main Results:

  • The transition from ropinirole IR to ropinirole PR was well-accepted and tolerated.
  • Once-daily dosing was achieved, simplifying the treatment regimen.
  • Faster titration and more stable plasma levels were observed with the PR formulation.

Conclusions:

  • Ropinirole PR represents a valuable advancement in Parkinson's disease pharmacotherapy.
  • The new formulation enhances patient convenience and treatment adherence.
  • It offers improved pharmacokinetic profiles and good tolerability compared to the IR version.